Specifically, it significantly decreased methylation at the promoter regions of BRCA1, GSTP1, and Eph receptor B2 (EPHB2) in DU-145 and PC-3 prostate cancer cell lines, leading to cell cycle arrest in the G0/G1 phase [181]. The gene discussed is GSTP1; the disease is prostate carcinoma.